Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation

Jeffrey R. Erickson, Laetitia Pereira, Lianguo Wang, Guanghui Han, Amanda Ferguson, Khanha Dao, Ronald J. Copeland, Florin Despa, Gerald W. Hart, Crystal M Ripplinger, Donald M Bers

Research output: Contribution to journalArticle

249 Citations (Scopus)

Abstract

Ca2+ /calmodulin-dependent protein kinase II (CaMKII) is an enzyme with important regulatory functions in the heart and brain, and its chronic activation can be pathological. CaMKII activation is seen in heart failure, and can directly induce pathological changes in ion channels, Ca 2+ handling and gene transcription. Here, in human, rat and mouse, we identify a novel mechanism linking CaMKII and hyperglycaemic signalling in diabetes mellitus, which is a key risk factor for heart and neurodegenerative diseases. Acute hyperglycaemia causes covalent modification of CaMKII by O-linked N-acetylglucosamine (O-GlcNAc). O-GlcNAc modification of CaMKII at Ser 279 activates CaMKII autonomously, creating molecular memory even after Ca 2+ concentration declines. O-GlcNAc-modified CaMKII is increased in the heart and brain of diabetic humans and rats. In cardiomyocytes, increased glucose concentration significantly enhances CaMKII-dependent activation of spontaneous sarcoplasmic reticulum Ca2+ release events that can contribute to cardiac mechanical dysfunction and arrhythmias. These effects were prevented by pharmacological inhibition of O-GlcNAc signalling or genetic ablation of CaMKIIδ. In intact perfused hearts, arrhythmias were aggravated by increased glucose concentration through O-GlcNAc- and CaMKII-dependent pathways. In diabetic animals, acute blockade of O-GlcNAc inhibited arrhythmogenesis. Thus, O-GlcNAc modification of CaMKII is a novel signalling event in pathways that may contribute critically to cardiac and neuronal pathophysiology in diabetes and other diseases.

Original languageEnglish (US)
Pages (from-to)372-376
Number of pages5
JournalNature
Volume502
Issue number7471
DOIs
StatePublished - 2013

Fingerprint

Calcium-Calmodulin-Dependent Protein Kinase Type 2
Glycosylation
Hyperglycemia
Cardiac Arrhythmias
Glucose
Acetylglucosamine
Brain
Sarcoplasmic Reticulum
Ion Channels
Cardiac Myocytes
Neurodegenerative Diseases
Heart Diseases
Diabetes Mellitus
Heart Failure
Pharmacology

ASJC Scopus subject areas

  • General

Cite this

Erickson, J. R., Pereira, L., Wang, L., Han, G., Ferguson, A., Dao, K., ... Bers, D. M. (2013). Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature, 502(7471), 372-376. https://doi.org/10.1038/nature12537

Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. / Erickson, Jeffrey R.; Pereira, Laetitia; Wang, Lianguo; Han, Guanghui; Ferguson, Amanda; Dao, Khanha; Copeland, Ronald J.; Despa, Florin; Hart, Gerald W.; Ripplinger, Crystal M; Bers, Donald M.

In: Nature, Vol. 502, No. 7471, 2013, p. 372-376.

Research output: Contribution to journalArticle

Erickson, JR, Pereira, L, Wang, L, Han, G, Ferguson, A, Dao, K, Copeland, RJ, Despa, F, Hart, GW, Ripplinger, CM & Bers, DM 2013, 'Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation', Nature, vol. 502, no. 7471, pp. 372-376. https://doi.org/10.1038/nature12537
Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 2013;502(7471):372-376. https://doi.org/10.1038/nature12537
Erickson, Jeffrey R. ; Pereira, Laetitia ; Wang, Lianguo ; Han, Guanghui ; Ferguson, Amanda ; Dao, Khanha ; Copeland, Ronald J. ; Despa, Florin ; Hart, Gerald W. ; Ripplinger, Crystal M ; Bers, Donald M. / Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. In: Nature. 2013 ; Vol. 502, No. 7471. pp. 372-376.
@article{a1e294157a3e43039887f5310bcd4951,
title = "Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation",
abstract = "Ca2+ /calmodulin-dependent protein kinase II (CaMKII) is an enzyme with important regulatory functions in the heart and brain, and its chronic activation can be pathological. CaMKII activation is seen in heart failure, and can directly induce pathological changes in ion channels, Ca 2+ handling and gene transcription. Here, in human, rat and mouse, we identify a novel mechanism linking CaMKII and hyperglycaemic signalling in diabetes mellitus, which is a key risk factor for heart and neurodegenerative diseases. Acute hyperglycaemia causes covalent modification of CaMKII by O-linked N-acetylglucosamine (O-GlcNAc). O-GlcNAc modification of CaMKII at Ser 279 activates CaMKII autonomously, creating molecular memory even after Ca 2+ concentration declines. O-GlcNAc-modified CaMKII is increased in the heart and brain of diabetic humans and rats. In cardiomyocytes, increased glucose concentration significantly enhances CaMKII-dependent activation of spontaneous sarcoplasmic reticulum Ca2+ release events that can contribute to cardiac mechanical dysfunction and arrhythmias. These effects were prevented by pharmacological inhibition of O-GlcNAc signalling or genetic ablation of CaMKIIδ. In intact perfused hearts, arrhythmias were aggravated by increased glucose concentration through O-GlcNAc- and CaMKII-dependent pathways. In diabetic animals, acute blockade of O-GlcNAc inhibited arrhythmogenesis. Thus, O-GlcNAc modification of CaMKII is a novel signalling event in pathways that may contribute critically to cardiac and neuronal pathophysiology in diabetes and other diseases.",
author = "Erickson, {Jeffrey R.} and Laetitia Pereira and Lianguo Wang and Guanghui Han and Amanda Ferguson and Khanha Dao and Copeland, {Ronald J.} and Florin Despa and Hart, {Gerald W.} and Ripplinger, {Crystal M} and Bers, {Donald M}",
year = "2013",
doi = "10.1038/nature12537",
language = "English (US)",
volume = "502",
pages = "372--376",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7471",

}

TY - JOUR

T1 - Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation

AU - Erickson, Jeffrey R.

AU - Pereira, Laetitia

AU - Wang, Lianguo

AU - Han, Guanghui

AU - Ferguson, Amanda

AU - Dao, Khanha

AU - Copeland, Ronald J.

AU - Despa, Florin

AU - Hart, Gerald W.

AU - Ripplinger, Crystal M

AU - Bers, Donald M

PY - 2013

Y1 - 2013

N2 - Ca2+ /calmodulin-dependent protein kinase II (CaMKII) is an enzyme with important regulatory functions in the heart and brain, and its chronic activation can be pathological. CaMKII activation is seen in heart failure, and can directly induce pathological changes in ion channels, Ca 2+ handling and gene transcription. Here, in human, rat and mouse, we identify a novel mechanism linking CaMKII and hyperglycaemic signalling in diabetes mellitus, which is a key risk factor for heart and neurodegenerative diseases. Acute hyperglycaemia causes covalent modification of CaMKII by O-linked N-acetylglucosamine (O-GlcNAc). O-GlcNAc modification of CaMKII at Ser 279 activates CaMKII autonomously, creating molecular memory even after Ca 2+ concentration declines. O-GlcNAc-modified CaMKII is increased in the heart and brain of diabetic humans and rats. In cardiomyocytes, increased glucose concentration significantly enhances CaMKII-dependent activation of spontaneous sarcoplasmic reticulum Ca2+ release events that can contribute to cardiac mechanical dysfunction and arrhythmias. These effects were prevented by pharmacological inhibition of O-GlcNAc signalling or genetic ablation of CaMKIIδ. In intact perfused hearts, arrhythmias were aggravated by increased glucose concentration through O-GlcNAc- and CaMKII-dependent pathways. In diabetic animals, acute blockade of O-GlcNAc inhibited arrhythmogenesis. Thus, O-GlcNAc modification of CaMKII is a novel signalling event in pathways that may contribute critically to cardiac and neuronal pathophysiology in diabetes and other diseases.

AB - Ca2+ /calmodulin-dependent protein kinase II (CaMKII) is an enzyme with important regulatory functions in the heart and brain, and its chronic activation can be pathological. CaMKII activation is seen in heart failure, and can directly induce pathological changes in ion channels, Ca 2+ handling and gene transcription. Here, in human, rat and mouse, we identify a novel mechanism linking CaMKII and hyperglycaemic signalling in diabetes mellitus, which is a key risk factor for heart and neurodegenerative diseases. Acute hyperglycaemia causes covalent modification of CaMKII by O-linked N-acetylglucosamine (O-GlcNAc). O-GlcNAc modification of CaMKII at Ser 279 activates CaMKII autonomously, creating molecular memory even after Ca 2+ concentration declines. O-GlcNAc-modified CaMKII is increased in the heart and brain of diabetic humans and rats. In cardiomyocytes, increased glucose concentration significantly enhances CaMKII-dependent activation of spontaneous sarcoplasmic reticulum Ca2+ release events that can contribute to cardiac mechanical dysfunction and arrhythmias. These effects were prevented by pharmacological inhibition of O-GlcNAc signalling or genetic ablation of CaMKIIδ. In intact perfused hearts, arrhythmias were aggravated by increased glucose concentration through O-GlcNAc- and CaMKII-dependent pathways. In diabetic animals, acute blockade of O-GlcNAc inhibited arrhythmogenesis. Thus, O-GlcNAc modification of CaMKII is a novel signalling event in pathways that may contribute critically to cardiac and neuronal pathophysiology in diabetes and other diseases.

UR - http://www.scopus.com/inward/record.url?scp=84885863770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885863770&partnerID=8YFLogxK

U2 - 10.1038/nature12537

DO - 10.1038/nature12537

M3 - Article

C2 - 24077098

AN - SCOPUS:84885863770

VL - 502

SP - 372

EP - 376

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7471

ER -